Who makes Tab SRT2104 intermediate release?

Tab SRT2104 intermediate release is developed by Sirtris, a GSK Company.

What development phase is Tab SRT2104 intermediate release in?

Tab SRT2104 intermediate release is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Tab SRT2104 intermediate release

Sirtris, a GSK Company · Phase 1 active Small molecule

At a glance

Generic name	Tab SRT2104 intermediate release
Sponsor	Sirtris, a GSK Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tab SRT2104 intermediate release CI brief — competitive landscape report
Tab SRT2104 intermediate release updates RSS · CI watch RSS
Sirtris, a GSK Company portfolio CI